Background: Disruption of bile acid (BA) homeostasis plays a key role in intestinal inflammation. The gut-liver axis is the main site for the regulation of BA synthesis and BA pool size via the combined action of the nuclear Farnesoid X Receptor (FXR) and the enterokine Fibroblast Growth Factor 19 (FGF19). Increasing evidence have linked derangement of BA metabolism with dysbiosis and mucosal inflammation. Thus, here we aimed to investigate the potential action of an FGF19 analogue on intestinal microbiota and inflammation. Methods: A novel engineered non-tumorigenic variant of the FGF19 protein, M52-WO 2016/0168219 was generated. WT and FXR null mice were injected with AAV-FGF19-M52 or the control AAV-GFP and subjected to Sodium Dextran Sulphate-induced colitis. Findings: FGF19-M52 reduced BA synthesis and pool size, modulated its composition and protected mice from intestinal inflammation. These events were coupled with preservation of the intestinal epithelial barrier integrity, inhibition of inflammatory immune response and modulation of microbiota composition. Interestingly, FGF19-M52-driven systemic and local anti-inflammatory activity was completely abolished in Farnesoid X Receptor (FXR) null mice, thus underscoring the need of FXR to guarantee enterocytes' fitness and complement FGF19 anti-inflammatory activity. To provide a translational perspective, we also show that circulating FGF19 levels are reduced in patients with Crohn's disease. Interpretation: Reactivation of the FXR-FGF19 axis in a murine model of intestinal inflammation could bona fide provide positive changes in BA metabolism with consequent reduction of intestinal inflammation and modulation of microbiota. These results point to the therapeutic potential of FGF19 in the treatment of intestinal inflammation with concomitant derangement of BA homeostasis.
Introduction
The Fibroblast growth factor FGF19 (FGF15/19) is an atypical member of the FGFs family, acting as a signalling gut hormone regulating bile acid (BA) metabolism, protein and glycogen synthesis and gluconeogenesis (reviewed in [1] ). It is expressed in the small intestine under the transcriptional control of the bile acids sensor Farnesoid X receptor (FXR) and its main physiological activities consist of the controlling BAs homeostasis during the transition from the fed to the fasted state [2À5] . BAs are detergent-like molecules synthesized from cholesterol in the liver, stored in the gallbladder, and released into the small intestine after food intake to facilitate the absorption of dietary lipids and liposoluble vitamins. Following the enterohepatic circulation, 95% of BA are then reabsorbed in the terminal ileum, secreted into the portal vein, and subsequently re-uptaken in the liver.
BAs act as signalling molecules via FXR [6À8] . FXR is a nuclear receptor highly expressed in the gut-liver axis that acts as the master regulator of BA homeostasis. BA-activated FXR finely controls BA homeostasis, regulating tissue-specific gene networks orchestrating their synthesis, transport and metabolism (reviewed in [9] ). De novo BA synthesis occurs in the liver via the classical biosynthetic pathways converting cholesterol into BAs. This pathway is controlled by a negative gut-liver feedback acting on the hepatic rate-limiting enzyme of BA synthesis Cholesterol 7 alpha-hydroxylase (CYP7A1). In the ileum, BA-dependent FXR activation induces the expression/ production of the enterokine FGF19 (FGF15 in the mouse), a hormone secreted in the portal circulation, able to reach the liver and bind to the fibroblast growth factor receptor 4 (FGFR4)/b-Klotho complex. FGF19-FGFR4/b-Klotho binding initiates a c-jun N-terminal kinasedependent pathway [4] , which ultimately leads to CYP7A1 repression.
Disrupted BA metabolism has been associated with an expanding record of chronic diseases, including metabolic [10, 11] , liver [12, 13] and intestinal diseases [14, 15] . Recent studies in humans have shown important relationships between FGF19 levels, BA synthetic rates and intestinal disorders [16À18], including intestinal inflammation. BAs have potent secretory effects on the colonic mucosa and when an excess of BA reaches the small bowel, the ileal capacity for BA absorption may be overwhelmed thus spilling them over into the colonic lumen and accelerating colonic transit. As a result, colonic motility and secretion are stimulated and diarrhea occurs. Patients suffering from BA malabsorption and diarrhea often exhibit increased levels of C4, a marker of hepatic BA synthesis, and reduced levels of the FGF19 [16À18] . The integrity of the enterohepatic circulation of BAs depends on the apical sodium bile acid transporter (ASBT) [19] and therapy with glucorticoids per se is able to induce human ABST in patients with Crohn's disease (CD) [20] . Also, it has been shown that the use of BA sequestrant in combination with glucocorticoids is beneficial in patients with CD with concomitant downregulation of ASBT [21] . Moreover, treatment of Asbt null mice with either a FXR agonist or Fgf15 downregulates hepatic Cyp7a1 mRNA levels, reduces the BA pool size, and reduces fecal BA excretion [22] . For these reasons, strategies aimed at restoring BA homeostasis through activation of the intestinal FXR-FGF19 signaling system hold promise in intestinal disorders with BA derangements. Indeed, pharmacological FXR activation inhibits intestinal inflammation and preserves the intestinal barrier integrity in chemically-induced models of intestinal inflammation and modulates the immune response in patients with inflammatory bowel disease (IBD) [15] . In addition, FXR null mice display a disrupted intestinal barrier at baseline, with severe degeneration after disruption of the BA flow via bile duct ligation [15, 23] . Notably, there is a strong interplay between the intestinal flora and BA metabolism. In fact, several studies have shown that the size and composition of circulating BAs have a crucial role not only in digestion, but also in shaping the gut microbial community [24] . BAs have intrinsic antimicrobial properties and via FXR activation they also regulate the expression of genes promoting innate defense [23, 25] . Viceversa, the intestinal microbiota plays a key role in regulating BA metabolism, and transforms primary into secondary BAs via bacterial-induced BA deconjugation and epimerization. This, in turn, shapes the magnitude of BA-induced FXR activation in the gut [26À29] . In experimental colitis, accumulation of BAs in the intestine leads to their disposal via the PPARa-UGT pathway [30] . This causes deregulation of the FXR transcriptional activity and compromises the Fxr-Fgf15 pathway activation, ultimately inducing continuous
Research in context
Evidence before this study Bile acids (Bas) are detergent-like molecules synthesized from cholesterol in the liver, stored in the gallbladder, and released into the small intestine after food intake to facilitate the absorption of dietary lipids and liposoluble vitamins. The farnesoid X receptor (FXR) is a nuclear receptor highly expressed in the gutliver axis that acts as the master regulator of BA homeostasis, mainly via the gut hormone Fibroblast growth factor FGF19 (FGF15/19). Disrupted BA metabolism has been associated with an expanding record of chronic diseases, including chronic intestinal inflammation. Strategies aimed at restoring BA homeostasis through activation of the intestinal FXR-FGF19 signalling system hold promise in intestinal disorders with concomitant BA derangements. Fifty percent of patients with chronic intestinal inflammation, and particularly Crohn's disease (CD) patients with inflammation of the terminal ileum, present with bile acid malabsorption and diarrhoea. This is due to decreased ASBT expression leading to impaired BA ileal re-uptake, lower FXR intestinal activation and consequent decreased production of FGF19 ultimately leading to loss of inhibition of hepatic Cyp7a1 and increased BA synthesis. This detrimental cascade worsens the vicious cycle in which higher BA levels undergo colonic spill over due to the decreased ileal ability to reabsorb them. Pharmacological FXR activation inhibits intestinal inflammation and preserves the intestinal barrier integrity in chemically-induced models of intestinal inflammation and modulates the immune response in patients with inflammatory bowel diseases, putatively via the action of FGF19.
Added value of this study
FGF19 is a putative major player in the inhibition of intestinal inflammation. In this study, we show for the first time the preclinical therapeutic exploitation of the enterokine Fibroblast Growth Factor 19 (FGF19) in experimental colitis. Our data powerfully show the multilevel ability of FGF19 in counteracting intestinal inflammation. First, FGF19 reduces intraluminal BA levels thus contributing to prevent the detergent cytotoxic events that further increase susceptibility to intestinal inflammation. This create the perfect environment for the subsequent anti-inflammatory boost generated by the beneficial shift in the intestinal microbiota. Concomitantly, FGF19 reduces local intestinal inflammation and immune response. Finally, it regulates enterocyte turnover and epithelial barrier integrity in mice competent for nuclear bile acid receptor FXR. In addition, in previously published papers, a negative relation between intestinal inflammation and FGF19 levels has only been shown in patient with CD (w/wo ileal resection) and concomitant BA diarrhea. This could theoretically influence data interpretation due to the lower intestinal ability to reabsorb BAs. Here, for the first-time data are presented from patients solely affected by CD without ileal resection and other concomitant conditions. Implication of all the available evidence Our data further strengthen the link between the regulation of BA homeostasis and inhibition of intestinal inflammation, highlighting the bona fide therapeutic potential of the FGF19 analogue M52 in the treatment of patient with intestinal inflammation and concomitant derangement of BA homeostasis. Our results are highly timely since similar FGF19 analogues are currently tested in phase 3 clinical trials for hepatic disease. activation of Cyp7a1, increased de novo BA synthesis and colitis exacerbation [30] . Finally, it is worth to state that several studies have suggested the therapeutic potential of FXR pharmacological activators as putative strategy in IBD [15, 31, 32] . In this study, we aimed to investigate the potential intestinal anti-inflammatory activity of FGF19. Since safety concerns have been raised about potential hepatic mitogenic FGF19 activity [33À37], recent studies dissected the FGF19 domains separately implicated in the retention of BA synthesis regulatory activity and its proliferative one [38, 39] . Therefore, we pre-clinically investigated the therapeutic potential of a novel engineered variant of the FGF19 protein, called FGF19-M52 (US patent US8951966B2), which is devoid of FGF19 hepatic pro-mitogenic capacity [12] . Here, we show for the first time that FGF19-M52 protects from experimental colitis in mice that are FXR competent. Since FGF19 analogues are being tested in clinic for liver disease, this discovery might bona fide open novel avenues in the therapeutic approach to IBD with concomitant BA derangements. 
Material and methods

Animals and Sodium Dextran Sulphate induced colitis
Bile salt measurements
Chenodeoxycholic Acid (CDCA), Cholic Acid (CA), Tauro-CDCA (T-CDCA), TCA and other endogenous BAs were purchased from Sigma-Aldrich (St. Louis, MO). All the studied BAs were identified and quantified by high-pressure liquid chromatography-electrospraymass spectrometry/mass spectrometry (HPLC-ES-MS/MS) by optimized methods [40] suitable for use in pure standard solution, plasma and liver samples after appropriate clean-up preanalytical procedures. Liquid chromatography analysis was performed using an Alliance HPLC system model 2695 from Waters combined with a triple quadruple mass spectrometer QUATTRO-LC (Micromass; Waters) using an electrospray interface. BAs were separated by elution gradient mode with a mobile phase composed of a mixture ammonium acetate buffer 15 mM, pH 8.0 (Solvent A) and acetonitrile: methanol = 75:25 v/v (Solvent B). Chromatograms were acquired using the mass spectrometer in multiple reactions monitoring mode. Biliary BAs were measured with the Total Bile Acid Assay (Dyazime, Dresden, Deutschland), according to the manufacturer's instructions.
Histology and Immunohistochemistry
Colon specimens were snap-frozen or fixed in 10% formalin (24h), dehydrated, and embedded in paraffin. Distal colon sections (5 mm) were stained with hematoxylin and eosin (H&E). Histopathological scoring was performed using an established semiquantitative score ranging from 0 to 6 based on infiltration of inflammatory cells and epithelial damage (1 = few inflammatory cells, no epithelial degeneration; 2 = mild inflammation, few signs of epithelial degeneration; 3 = moderate inflammation, few epithelial ulcerations; 4 = moderate to severe inflammation, ulcerations in 25À50% of the tissue section; 5 = moderate to severe inflammation, large ulcerations in >50% of the tissue section; 6 = severe inflammation and ulcerations of >75% of the tissue section) [41] . Depletion of goblet cells was scored using a scoring index from 0 to 4 (0 = no depletion; 1 = 0À10% depletion; 2 = 10À25% depletion; 3 = 25À50% depletion; 4 = 50À100% depletion). Immunohistochemical (IHC) detection was performed on thin section (4um) of paraffin embeeded tissue. After Antigen retrieval, the sections were blocked with proteine blocking serum free (X0909, Dako). Antibody to F4/80 (CI:A3-1; 1:200) was incubated on slides at RT for 1h and detected by the Dako REAL EnVision Detection System Peroxidase/DAB according to manufacturer's instruction (K5007, Dako). Hematoxylin was used to counterstain. Stained slides were scanned on an AperioScanScope AT and image analysis and quantification was performed using AperioImageScope software (Leica Biosystems, Nussloch, Germany). Signal was normalized to area and image analyses were done using Aperio algorithms (Leica Biosystems). Analysis was performed by an investigator blinded to study design with results confirmed by an independent investigator.
In vivo intestinal permeability assay
In vivo intestinal permeability was assessed in mice on the day of sacrifice, as previously described [42] . Mice were gavaged with 0.6 mg/g body weight of fluorescein isothiocyanate (FITC)-conjugated dextran (Sigma, S Louis, Missouri, USA; molecular mass 3e5 kDa) for 4h. Blood was collected, and FITC concentrations were measured in plasma with the Microplate fluorometer VICTOR TM EnLite TM (PerkinElmer, Inc., Italy). Serum fluorescence intensity positively correlates with increased intestinal permeability.
mRNA extraction and quantitative real time qRT-PCR analysis
RNA was isolated from liver and colon of mice using RNeasy Micro kit (Qiagen, Milano, Italy). cDNA was generated from 4mg total RNA using High Capacity DNA Archive Kit (Applied Biosystem, Foster City, CA) and following the manufacturer's instructions. Primers to detect the mRNA expression level of each gene were designed using Primer Express software (Applied Biosystem) based on Gene Bank sequence data. mRNA expression levels were quantified by qRTPCR using Power Syber Green chemistry and normalized to cyclophillin mRNA levels. Validated primers for qRT-PCR are available upon request.
Metagenomic sequencing of cecal content samples
Microbiome analysis was performed by Vaiomer (www.vaiomer. com/). Bacterial populations contained in the samples were determined using next generation high throughput sequencing of variable regions (V3-V4) of the 16S rDNA bacterial gene and a metagenomic workflow, exclusive to bacteria and established by Vaiomer [43] , was used to identify organisms from a sample by amplifying specific regions in the 16S ribosomal RNA gene. PCR amplification was performed using 16S universal primers targeting the V3-V4 region of the bacterial 16S ribosomal gene (Vaiomer universal 16S primers). The joint pair length was set to encompass 467 base pairs amplicon thanks to 2 £ 300 paired-end MiSeq kit V3. For each sample, a sequencing library was generated by addition of sequencing adapters. The detection of the sequencing fragments was performed using MiSeq Illumina Ò technology. The targeted metagenomic sequences from microbiota were analyzed using the bioinformatic pipeline established by Vaiomer from the FROGS guidelines [44] . Briefly, after demultiplexing of the bar-coded Illumina paired reads, single read sequences are cleaned and paired for each sample independently into longer fragments. Operational taxonomic units (OTUs) were produced with via single-linkage clustering and taxonomic assignment was performed in order to determine community profiles. Reads obtained from the MiSeq sequencing system have been processed using Vaiomer bioinformatic pipeline. The steps include quality-filtering, clustering into OTUs with the Swarm algorithm and taxonomic affiliation. Data are available on the ENA database (accession number PRJEB36966).
RNA extraction and quantitative real time qRT-PCR analysis in IBD patients
Ileal patients' biopsies from CD patients (n = 6 with inflamed mucosa localization; n=6 from adjacent macroscopically healthy mucosa) were obtained from Humanitas Institute. RNA was isolated using RNeasy Micro kit (Qiagen, Milano, Italy). cDNA was generated from 1mg total RNA using High Capacity DNA Archive Kit (Applied Biosystem, Foster City, CA) and following the manufacturer's instructions. Human primers to detect mRNA expression level of each gene were designed using Primer Express software (Applied Biosystem) based on Gene Bank sequence data. mRNA expression levels were quantified by qRTPCR using Power Syber Green chemistry and normalized to cyclophillin mRNA levels. Validated human primers for qRT-PCR are available upon request.
FGF19 quantification in IBD patients
Plasma samples from CD patients (n = 57 all with ileal disease localization, 19 with active disease and 38 in remission) and healthy controls (n=23) were obtained from Humanitas Institute and our own biobank, respectively. Written informed consent was obtained from the participants of the study. Ethical approval was obtained by the independent ethical committees of the Humanitas Institute ethical committee (Dept. of Gastroenterology and Digestive Endoscopy; n.345, 2006) and the University Hospital of Bari (Interdisciplinary Department of Medicine; n.311, MSC/PBMC/2015). ELISA for human FGF19 was performed using biotin-labelled antibody pairs and standards provided by Biovendor (Bologna, Italy), according to the manufacturers' procedures.
Statistical Analysis
All results are expressed as means §standard error of the mean (SEM). Significant differences between two or more groups were determined by Mann-Whitney's U and Kruskal-Wallis tests, as appropriate. All statistical analyses were performed with GraphPad Prism software (v5.0; GraphPad Software Inc., San Diego, CA) and conducted as a two-sided alpha level of 0.05.
Results
FGF19 M52 analogue retains BA-synthesis regulatory activity
In order to study the therapeutic potential of FGF19 in intestinal inflammation, a novel engineered variant of the FGF19 protein, M52 (see WO 2016/0168219), was obtained from NGM Biopharmaceuticals, Inc. M52 differs from WT FGF19 by five amino acid substitutions (A30S, G31S, H33L, V35L, H36Q) and fiveÀamino acid deletion at the N terminus. When compared to the full-length form in vivo, this variant retains its biological activity of repression of de novo BA synthesis while showing no hepatic tumorigenic activity [12] . We then tested M52 capability of controlling BA homeostasis in our colitis model. WT mice were injected with either the adeno-associated virus (AAV) containing either the FGF19-M52 analogue or GFP, and then subjected to DSS-induced colitis. Compared to the control group, AAV-FGF19-M52-injected mice displayed a significant lower hepatic mRNA expression of the key limiting enzymes of BA synthesis Cyp7a1, Cyp7b1 -a cytochrome that has a minor role in the conversion of cholesterol into BAs -and Cyp8b1 that regulates the relative amount of CDCA and CA (Fig. 1a) . These changes were translated into a 50% reduction of the plasmatic BA pool size (AAV-GFP 2.37 § 0.75 vs AAV-FGF19-M52 1.65 § 0.93 mM), 35% reduction of the biliary bile acid pool size (Fig. 1b) and a shift in plasma BA composition to a more hydrophilic BA pool profile due to the enrichment in muricholic acid (MCA) (Fig. 1c) .
FGF19 M52 analogue protects from DSS-induced colitis
We then investigated whether the FGF19 analogue M52 confers protection against DSS-induced colitis. In WT C57Bl/6J mice, AAV-FGF19-M52 injection significantly reduced the typical symptoms of intestinal inflammation, including body weight loss, visible rectal bleeding and occurrence of occult blood in mouse stools (Fig. 1dÀf) . Moreover, FGF19-M52 prevented colonic shortening compared to control AAV-GFP injected mice (Fig. 1g) .
Histological analysis showed that DSS-induced colitis was associated with a severe disruption of the epithelial layer and acute inflammatory infiltrates in WT mice injected with AAV-GFP (Fig. 1h) . In sharp contrast, AAV-FGF19-M52-injected WT mice showed significantly less morphological alteration and decreased inflammatory infiltrates (Fig. 1i) . Patients with chronic intestinal inflammation presenting with clinically and endoscopically significant colitis display various degrees of mucin-secreting goblet cells loss [45] , and the epithelial barrier is often already compromised at early stages of the disease, leading to bacterial translocation and inflammation [46, 47] . Therefore, we assessed this disease index in our experimental model. Goblet cell loss due to DSS-induced inflammation was significantly less in AAV-FGF19-M52-injected WT mice compared to the control AAV-GFP group. A histopathological score method was applied and quantification of histological disease index and Goblet cell loss is shown (Fig. 1j, k) . In a preliminary experiment performed to test appropriate DSS concentration, WT mice were treated with 5% DSS for 7 days. Results show a strong significant FGF19-M52-dependent protection from mortality compared to AAV-GFP-injected mice (10% mortality in FGF19-M52-vs 60% in GFP-injected mice, Supplementary Figure 1 ).
FGF19 analogue M52 decreases DSS-induced intestinal permeability in vivo
Protection from goblet cell loss due to FGF19-M52 treatment suggested a preservation of the intestinal epithelial barrier integrity. We assessed this in vivo with a FITC-dextran based intestinal permeability assay. FGF19-M52 protected from DSS-dependent increased epithelial permeability. Plasma levels of FITC-conjugated dextran were almost completely abolished in AAV-FGF19-M52-injected mice compared to the control group (Fig. 1l) . These data point to a putative direct protective effect of FGF19-M52 in the enterocyte turnover and integrity.
FGF19 analogue M52 strengthens the integrity of the epithelial barrier and decreases local inflammatory response
The intestinal epithelium is a physical barrier consisting of enterocytes tightly connected via intercellular junctions. It is constantly renewed every 3-5 days by stem cells residing at the bottom of the intestinal crypts. The majority of these cells migrate towards the top of intestinal villi while their molecular signature undergoes a switch from proliferative to differentiative pattern. The "enterocyte" phenotype is coupled with a progressive increased expression of differentiation markers such as the caudal homeobox domain 2 (CDX2) [48] and the Kr€ uppel-like factor 4 (KLF4) [49] , a gene involved in appropriate localization of the different intestinal cell lineage and epithelium homeostasis in the fully differentiated enterocytes. The intestinal epithelium separates the intestinal lumen from the lymphoid tissue associated with the gastrointestinal system, preventing external antigens and micro-organisms from entering the body while maintaining tolerance to harmless organisms [50] . Additionally, enterocytes contribute to trigger the inflammatory response by secreting pro-inflammatory cytokines and chemokines. Together with loss of epithelial barrier integrity, human intestinal chronic inflammation arises concomitantly with dysregulation of the mucosal immune response caused by a shift of balance from secretion of antiinflammatory mediators towards pro-inflammatory molecules. For this reason, we investigated the ability of the non-tumorigenic FGF19-M52 analogue of modulating inflammatory and intestinal barrier gene expression during colitis. AAV-FGF19-M52-injected mice displayed a striking decrease of the colonic mucosa pro-inflammatory cytokine interleukin (IL)-1b, IL-6 and Tumor Necrosis Factor a (Fig. 2a) . Intestinal immunohistochemical analysis of the inflammatory marker F4/80 shows that AAV-FGF19-M52 remarkably decreases macrophage recruitment at the site of inflammation compared to AAV-GFP-injected mice (Fig. 2b) . This is associated with a strong induction of several members of tight junction proteins that have been shown to be downregulated in patients affected by IBD [51] , namely Claudin 2, Claudin 3, Claudin 12 and Occludin (Fig. 2c) . At the same time, the snapshot of gene expression pattern shows a dramatic increase of the differentiation markers Cdx2 and Klf4 in AAV-FGF19-M52-injected mice compared to the control group (Fig. 2d) . Taken together, these data indicate that FGF19-M52 on the one hand decreases intestinal BA cytotoxicity and on the other hand, it inhibits the mucosal inflammatory immune response and preserves the epithelial barrier integrity by boosting the enterocytes ability to renew the intestinal epithelial barrier.
AAV-FGF19-M52 provides a beneficial shift in the intestinal flora of WT mice
In order to understand whether FGF19-dependent reduction of BA synthesis and modulation of its composition together with protection from experimental colitis is paralleled by a change in the intestinal microbial composition we have sequenced the 16S rDNA extracted from cecal content of mice of our experimental groups. Alpha diversity analysis at OTU level shows a significant difference between WT mice treated with AAV-FGF19-M52 and AAV-GFP (Fig. 3a) . Bray Curtis beta diversity analysis and hierarchical clustering show a major separation between WT mice injected with AAV-GFP and AAV-FGF19-M52 (Fig. 3b) . Then, we focused on clade abundance to identify which microbial clades where modified by AAV-FGF19-M52 in WT mice and LEfSe analysis was performed on the sequence data [52] . AAV-FGF19-M52-injected mice subjected to experimental colitis show a beneficial bacterial shift compared to the control group. The highest mean of differential features at genus level are represented by tenericutes, mollicutes, acetatifactor, butyricicoccus, anaeroplasmateles, anaeroplasma and anaeroplasmataceae (Fig. 3c ).
FXR is necessary for FGF19 analogue M52-dependent protection against colitis
FGF19 is an intestinal target of FXR and loss of FXR has been show to increase susceptibility to inflammation and cancer [15, 53] . We then tested if AAV-FGF19-M52 is able to reduce BA concentration in (Fig. 4a) . Regardless, we observed a shift in plasma BA composition to a more hydrophilic BA pool profile due to the enrichment in MCA in AAV-FGF19-M52 mice compared to control mice (Fig. 4b) . Difference in regulation of Cyp7a1 and Cyp8b1 via FGF19 is possibly ascribable to DSS ability to change BA metabolism and expression of related cytochromes [30] . Interestingly, no evident signs of FGF19-M52-dependent protection against DSS-induced symptoms were detected in FXR null mice (Fig. 4cÀf) . These results were paralleled by no changes of the microscopic intestinal structure features, as indicated by HE staining and analysis of the colonic morphology and assessment of inflammatory infiltrate and goblet cell loss (Fig. 4gÀj) . In line with these data, FGF19-M52 did not provide an improvement of the intestinal barrier integrity (Fig. 4k ) nor any significant difference in macrophage recruitment at the inflammation site and pro-inflammatory and tight-junctions gene expression levels, except Claudin 3 (Fig. 5aÀc) . Moreover, no changes in Cdx2 and Klf4 gene expression levels were observed (Fig. 5d) . Taken together, these data indicate first that FGF19 is sufficient to modulate BA homeostasis even in the absence of FXR. However, the presence of FXR is necessary for the FGF19 antiinflammatory response in the gut and for enterocyte differentiation and preservation of the intestinal barrier integrity.
AAV-FGF19-M52 does not provide a beneficial shift in the intestinal flora of FXR null mice
In order to explore FGF19-M52-dependent changes in intestinal microbial composition of Fxr null mice we have sequenced the 16S rDNA extracted from cecal content of mice of our experimental groups. Alpha and beta diversity analysis did not show a significant difference between Fxr null mice injected with either AAV-GFP or AAV-FGF19-M52 (Fig. 6a, b) . Moreover, clade abundance query indicates that the positive modulation of intestinal microbiota obtained in WT mice via FGF19-M52 treatment is lost in FXR null mice, just as lost is the protection against inflammation and epithelial integrity (Fig. 6c) .
Systemic FGF19 levels are lower in patients affected by Crohn's Disease
Since chronic active inflammation in patients with CD is known to affect the normal structure of the intestinal mucosa and decrease FXR intestinal transcriptional activity [54] , we wanted to asses intestinal and systemic expression of FGF19. Using two different biopsies from the same CD patient (tot. n = 6 pts), one located in the actively inflamed area and the other one from the adjacent macroscopically not inflamed one, we assessed levels of genes that are normally expressed in the differentiated compartment of the intestinal mucosa. Relative mRNA levels of the differentiation markers Villin, Sucrose Isomaltase (SI) and CDX2 are significantly lower in the region affected by active inflammation compared to the uninflamed one ( Supplementary Fig. 2aÀc ). We then assessed whether the expression of the FXR targets FGF19 and intestinal bile acid binding protein (IBABP) were affected. mRNA levels of IBABP resulted significantly decreased and FGF19 showed a strong decreasing trend (Fig. 7aÀc) in the actively inflamed mucosa compared to the adjacent macroscopically healthy one. We then measured FGF19 circulating levels in the serum of healthy controls and CD patients. Circulating FGF19 levels are strikingly lower in patients with CD in remission and even lower in CD patients with active inflammation compared to control subjects (Fig. 7d) . Overall, these data point to the existence of a downregulation of intestinal FXR activity with decreased circulating levels of FGF19 in patients with CD.
Discussion
BA metabolic derangements are one of the wide causal phenotype heterogeneity of patients presenting with chronic intestinal inflammation. In fact, fifty percent of IBD patients, and particularly CD patients with inflammation of the terminal ileum, present with bile acid malabsorption and diarrhea [55] . This is putatively due to decreased ASBT expression [56] leading to increased intraluminal detergent BA via impaired BA ileal re-uptake, lower FXR intestinal activation [18, 54] and consequent decreased production of the FXR major target FGF19 [16, 57] . This, ultimately cause a vicious cycle priming loss of inhibition of hepatic Cyp7a1 and increased BA synthesis. In experimental colitis, accumulation of BAs in the intestine leads to their disposal via the PPARa-UGT pathway [30] . This causes deregulation of the FXR transcriptional activity and a compromised FxrFgf15 pathway activation, ultimately leading to continuous activation of Cyp7a1, increased de novo BA synthesis and colitis exacerbation [30] . In this study we describe a novel non-tumorigenic FGF19 variant, FGF19-M52, as a potential therapeutic agent for intestinal inflammation. For the first time, here we show that FGF19-M52 successfully protects WT mice from DSS-induced symptoms of inflammation, reduces mucosal pro-inflammatory gene expression and immune response, preserves the intestinal barrier integrity and induces a beneficial microbial shift contributing to the resolution of the inflammatory phenotype. In particular, FGF19-M52 reduced biliary and plasmatic BA pool size and induced a beneficial shift in plasma BA composition to a more hydrophilic pool profile by repressing hepatic BA synthesis, thereby protecting from colitis development. In contrast with previously published data [58] , Asbt expression level do not change upon FGF19 treatment (data not shown). This is likely due to the fact that in our model inflammation is induced upon DSS administration, resulting in colonic inflammation, a condition in which ileal Asbt expression does not appear to be affected [59] . Moreover, FGF19-M52 also showed a local anti-inflammatory and proturnover activity. In fact, FGF19-M52 inhibited the mucosal inflammatory immune response and boosted enterocytes' ability to renew the intestinal epithelial barrier preserving its integrity during an inflammatory stimulus. Since FGF19 is an intestinal target of FXR and loss of FXR has been show to increase susceptibility to inflammation and cancer [15, 53] , we asked ourselves whether FGF19-M52 is able to reduce BA concentration in FXR null mice via repression of hepatic Cyp7a1 and if this event is coupled with protection against inflammation even in the absence of FXR. Our results in FXR null mice indicate that FXR is necessary in the FGF19-mediated protection from DSS-induced intestinal inflammation and that its expression/activity has probably a local and basal physiological function in the maintenance of the intestinal barrier integrity. In fact, Fxr null mice display a disrupted intestinal barrier at baseline, with severe degeneration after obstruction of the BA flow via bile duct ligation [15, 23] . Here, we show that FXR is unconditionally necessary in protecting from intestinal inflammation and most likely it complements FGF19 anti-inflammatory activity in the preservation of intestinal homeostasis. Mechanistically, this could be explained considering the beneficial action of FGF19 in rendering circulating BA pool more favourable for the coordination of intestinal self-renewal of intestinal cells [60] . In both human and mice, the exact nature of the host-microbiome interaction contributing to chronic intestinal inflammation development has not been completely defined. Metagenomic techniques are greatly aiding the identification of bacterial species, functions and metabolites involved in the development of chronic intestinal inflammation. In an attempt to discover whether FGF19 anti-inflammatory effect was exploited also via a shift in the gut flora, we embarked in microbiome analysis of cecal samples of WT and FXR null mice. Our results show that FGF19-M52 generates a beneficial shift in the intestinal bacterial composition of WT mice, with an increased abundance of butyricicoccus, tenericutes and acetatifactor, belonging to firmicutes and butyrate producers, known to be decreased in patient with inflammatory bowel disease. Although we are far from a complete understanding of bacterial dysbiosis in chronic intestinal inflammation and other gut disorders and the relative importance of bacterial species is still under debate, the species we have unveiled in our study have previously been associated with protection against IBD [61] [62] [63] [64] and therefore may be beneficially involved in the maintenance of gut fitness. Interestingly, it has previously been shown that an advantageous intestinal milieu contributes to the inhibition of BAs synthesis by promoting the intestinal activity of the Fxr-Fgf15 duo [29] . On the contrary, it is striking to note that the positive effects of FGF19-M52 on the intestinal microbiota are lost in FXR null mice just as lost is the protective effects against colitis and the promotion of cell renewal. Taken together, these data indicate that the FXR-FGF19 duo protects from intestinal inflammation by modulating the BA pool size and composition, counteracting the local inflammatory response and tuning the gut bacterial composition, with FXR playing a critical role in promoting intestinal cell renewal in the context of an inflammatory injury. First, FGF19 reduces the biliary and intraluminal BA levels thus reducing the detergent cytotoxic events that further increase susceptibility to intestinal inflammation in IBD patients. This creates the perfect environment for the subsequent anti-inflammatory boost generated by the beneficial shift in the intestinal microbiota. Concomitantly, FGF19 reduces local intestinal inflammation and immune responses and preserves the intestinal barrier integrity. Finally, FGF19 regulates enterocyte turnover and preserves the epithelial barrier integrity only in mice competent for FXR. Several clinical trials for hepatic and metabolic diseases using FGF19 analogues have been recently successfully concluded [2, [65] [66] [67] [68] while others are ongoing, indicating that its therapeutic potential has just started to be uncovered and might soon be extended to other pathological condition. Safety profile for another FGF19 analogue, namely M70/NGM282, have indicated mild to moderate adverse event in the trialled patients, such as diarrhea, increased intestinal transit and abdominal discomfort. Therefore, despite its efficacy in treating different metabolic and inflammatory conditions, patients might benefit in the future also from studies with the novel analogue M52.
In conclusion, our data strengthen the link between the BA homeostasis, intestinal inflammation and microbiota composition, highlighting the bona fide therapeutic potential of the FGF19 analogues in the treatment of IBD patients where concomitant derangement of BA homeostasis is diagnosed.
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